Skip to main content

Advertisement

Table 4 Predictive factors of 2-year recurrence rate

From: The short-term efficacy of no-touch radiofrequency ablation in treating cirrhosis-based small hepatocellular carcinoma

Variables N Univariate analysis Multivariate analysis
HR (95% CI) P value HR (95% CI) P value
Gender, male 120 1.46 (0.19–10.99) 0.713 1.44 (0.19–10.73) 0.725
Age (years)
  < 40(ref) 14     
 40–60 91 1.51 (0.65–3.82) 0.633   
  > =60 25 2.70 (0.55–8.15) 0.221   
BMI (kg/m2), > = 24 61 1.71 (0.76–3.84) 0.193   
Cirrhotic state, Uncompensated 32 1.09 (0.44–2.72) 0.849   
APRI
  < 0.5(ref) 32     
 0.5–1.5 64 0.72 (0.22–2.39) 0.590   
  > =1.5 34 1.19 (0.46–3.07) 0.723   
Pre-treatment ascites 18 4.83 (0.65–35.77) 0.124   
Pre-treatment EGV 7 1.22 (0.39–2.16) 0.256   
Tumor size (mm), > 20 64 1.13 (0.52–2.45) 0.756   
ALT (IU/L), > 40 47 1.29 (0.56–2.96) 0.551   
AST (IU/L), > 40 45 2.28 (0.86–6.05) 0.098 2.25 (0.85–5.98) 0.104
PT (sec), > 13 23 1.29 (0.38–4.38) 0.683   
ALP (IU/L), > 110 41 1.84 (0.73–4.63) 0.194   
TBA (μmol/L), > 10 48 1.11 (0.50–2.49) 0.799   
ALBI grade
 1(ref) 98     
 2 32 1.04 (0.42–2.61) 0.931   
 3 0     
PLT(10^9/L), < 100 53 1.03 (0.47–2.29) 0.939   
AFP (ng/ml), > 20 59 1.08 (0.50–2.35) 0.849   
Child-Pugh, B 11 1.62 (0.62–4.69) 0.214   
Conventional RFA 84 2.12 (1.16–4.62) 0.027 2.11 (1.16–4.43) 0.041
  1. RFA radio frequency ablation, BMI body mass index, APRI Aspartate aminotransferase-to-Platelet Ratio Index, ALT alanine aminotransferase, AST aspartate aminotransferase, PT Prothrombin time, ALP alkaline phosphatase, EGV esophago-gastric Varices, TBA total bile acid, ALBI albumin-bilirubin grade for HCC, PLT platelet count, AFP alpha-fetoprotein